Unlocking the potential of the immune system. IMU's cutting-edge platform decodes complex immune challenges to drive breakthroughs and better health outcomes.
Location: United Kingdom
Total raised: $68M
Investors 3
| Date | Name | Website |
| 08.06.2026 | IQ Capital... | iqcapital.... |
| 03.04.2024 | Molten Ven... | moltenvent... |
| - | COREangels... | coreangels... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.06.2026 | Series A | $53M | IQ Capital... |
| 24.01.2024 | Series A | $15M | - |
Mentions in press and media 14
| Date | Title | Description |
| 09.09.2026 | IMU Biosciences and Eurofins Transplant Genomics Form Strategic Partnership to Advance Transplant-Related Clinical Development Programmes | - |
| 24.06.2026 | IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine | IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time. Waters Biosciences' technologies, including BD FACSDiscover™ and BD Rhapso... |
| 24.06.2026 | IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine | IMU Biosciences, a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose, and treat disease, and Waters Corporation (NYSE: WAT) today announced a strategic partnership to accelerate the ... |
| 08.06.2026 | Europe's AI Revolution: Billions Fuel Tech Boom, Factorial Leads $2.5B Charge | European tech is booming. Billions in capital flow weekly into innovative startups. AI innovation powers this massive surge. Workforce management giant Factorial just secured $150 million in Series D funding. Its valuation hit $2.5 billion.... |
| 08.06.2026 | European tech weekly recap: Over €2.3B invested in the tech ecosystem in the first week of June | Last week, we tracked more than 55 tech funding deals worth over €2.3 billion and over 10 exits, M&A transactions, rumours, and related news stories across Europe. 📊 The top three industries that raised the most were analytics (€862.2 m... |
| 02.06.2026 | IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transfor... | IMU Biosciences (‘IMU or the ‘Company’), a biotechnology company decoding the immune system to pioneer a paradigm shift in how we understand, diagnose and treat disease, has successfully brought its Series A to over $53 million (£40 million... |
| 02.06.2026 | IMU Biosciences Raises Additional Capital; Series A funding Reaches Over $53M | IMU Biosciences, a London, UK-based developer of a high-resolution immune system decoding and multi-omic analysis platform, raised additional capital to bring its Series A funding round to over $53M (£40M). The round was co-led by IQ Capita... |
| 02.06.2026 | IMU Biosciences Secures $53M to Advance Immune Tech | IMU Biosciences has secured a $53 million (£40 million) Series A fundraising round, bringing the total raised in the round to more than double the original amount. This huge vote of confidence highlights the faith the market has in IMU’s AI... |
| 25.01.2024 | IMU Biosciences, participada por K Fund, cierra una ronda de £ 11,5M liderada por Molten Ventures. Participan LifeX Ventures y business angels | 25/01/2024 Nota de prensa IMU BIOSCIENCES, PARTICIPADA POR K FUND, CIERRA UNA RONDA DE £ 11,5M LIDERADA POR MOLTEN VENTURES. PARTICIPAN LIFEX VENTURES Y BUSINESS ANGELS Estamos encantados de compartir que IMU Biosciences, una empresa partic... |
| 24.01.2024 | IMU Biosciences Raises £11.5M in Series A Funding | IMU Biosciences, a London, UK-based techbio company working in the field of the immune powered precision medicine, raised £11.5M in Series A funding. The round was led by Molten Ventures. The company intends to use the funds to accelerate i... |
Show more